Related Experiment Video
Updated: Jan 20, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials
Rossella Avallone1, Giovanni Vitale2, Marco Bertolotti3
1Department of Life Sciences, Modena and Reggio Emilia University, 41125 Modena, Italy. rossella.avallone@unimore.it.
Abstract:
A nutritional approach could be a promising strategy to prevent or slow the progression of neurodegenerative diseases such as Parkinson's and Alzheimer's disease, since there is no effective therapy for these diseases so far. The beneficial effects of omega-3 fatty acids are now well established by a plethora of studies through their involvement in multiple biochemical functions, including synthesis of anti-inflammatory mediators, cell membrane fluidity, intracellular signaling, and gene expression. This systematic review will consider epidemiological studies and clinical trials that assessed the impact of supplementation or dietary intake of omega-3 polyunsaturated fatty acids on neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. Indeed, treatment with omega-3 fatty acids, being safe and well tolerated, represents a valuable and biologically plausible tool in the management of neurodegenerative diseases in their early stages.
Related Concept Videos
09:09In Silico Clinical Trials for Cardiovascular Disease
07:27Olfactory Assays for Mouse Models of Neurodegenerative Disease
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
10:43Preparation, Purification, and Use of Fatty Acid-containing Liposomes
08:41Identification of Fatty Acids in Bacillus cereus

